A Phase 1, Single Center, Double-blind, Randomized, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TC-5214 (S-Mecamylamine) After Administration of Single and Multiple Ascending Doses for up to 8 Days in Healthy Male and Female Subjects.

Trial Profile

A Phase 1, Single Center, Double-blind, Randomized, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TC-5214 (S-Mecamylamine) After Administration of Single and Multiple Ascending Doses for up to 8 Days in Healthy Male and Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Dexmecamylamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2010 Actual end date changed from Nov 20104 to Aug 2010 as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Actual initiation date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top